These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30240691)

  • 1. Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive Bladder.
    De Wachter S; Benson KD; Dmochowski RR; Rovner ES; Versi E; Miller LE; Tu LM
    J Urol; 2019 Mar; 201(3):573-580. PubMed ID: 30240691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year results with selective bladder denervation in women with refractory overactive bladder.
    Rovner ES; Versi E; Le Mai T; Dmochowski RR; De Wachter S
    Neurourol Urodyn; 2019 Nov; 38(8):2178-2184. PubMed ID: 31359508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial clinical experience with selective bladder denervation for refractory overactive bladder.
    Tu LM; De Wachter S; Robert M; Dmochowski RR; Miller LE; Everaert K
    Neurourol Urodyn; 2019 Feb; 38(2):644-652. PubMed ID: 30499155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does urinary urgency drive urinary frequency in overactive bladder?
    Versi E; Rovner ES; Dmochowski RR; Tu LM; De Wachter S
    Low Urin Tract Symptoms; 2022 Jul; 14(4):242-247. PubMed ID: 35233968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Preliminary Study on the Impact of Detrusor Overactivity on the Efficacy of Selective Bladder Denervation for the Treatment of Female Refractory Overactive Bladder.
    Brière R; Versi E; Richard PO; Gratton M; Tu LM
    Urology; 2020 Feb; 136():88-94. PubMed ID: 31794815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study.
    Goudelocke C; Xavier K; Pecha B; Burgess K; Perrouin-Verbe MA; Krlin R; Michaels J; Shah S; Peyronnet B; Zaslau S; Champs M; Papi B; Bittner K; Elterman D; Nitti V
    Neurourol Urodyn; 2023 Apr; 42(4):761-769. PubMed ID: 36917003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
    Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
    J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.
    Yokoyama O; Yamagami H; Hiro S; Hotta S; Yoshida M
    Int J Urol; 2018 Mar; 25(3):251-257. PubMed ID: 29224251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study.
    Gilling P; Meffan P; Kaaki B; MacDiarmid S; Lucente V; Clark M; Sen SK; English S; Sand PK
    Urology; 2021 Nov; 157():71-78. PubMed ID: 34048826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective assessment of overactive bladder symptoms in a cohort of elderly women who underwent transvaginal surgery for advanced pelvic organ prolapse.
    Foster RT; Barber MD; Parasio MF; Walters MD; Weidner AC; Amundsen CL
    Am J Obstet Gynecol; 2007 Jul; 197(1):82.e1-4. PubMed ID: 17618768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.
    Heesakkers JPFA; Digesu GA; van Breda J; Van Kerrebroeck P; Elneil S
    Neurourol Urodyn; 2018 Mar; 37(3):1060-1067. PubMed ID: 28892221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.